|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
Pt 7
|
|
pubmed:dateCreated |
2007-7-10
|
|
pubmed:abstractText |
Glucagon and glucagon-like peptide 1 (GLP-1) are drugs or drug candidates for the treatment of metabolic diseases such as diabetes and obesity. The native hormones have pharmacological deficiencies such as short half-life and poor solubility. A novel glucagon receptor agonist named glucagon-Cex has been designed, synthesized and crystallized. This peptide was highly soluble under physiological conditions and crystallized readily. The crystal diffracted X-rays to 2.2 A resolution and the diffraction was consistent with space group P23, with unit-cell parameters a = b = c = 48.20 A, alpha = beta = gamma = 90.0 degrees. The crystals were suitable for a full structural determination to reveal the conformational differences between glucagon-Cex and the native hormone.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-10837469,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-11683627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-12007541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-12769729,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-12832104,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-1478777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16144950,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16462409,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16530126,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16617231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16712485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-16922822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-17077190,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-5700707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-6391993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-7851494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-8396143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-9285204,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17620721-9840447
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1744-3091
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
599-601
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Design, synthesis and crystallization of a novel glucagon analog as a therapeutic agent.
|
|
pubmed:affiliation |
Department of Chemistry and Biochemistry Program, Indiana University, Bloomington, Indiana 47405, USA.
|
|
pubmed:publicationType |
Journal Article
|
